Prometheus Biosciences, Inc. financial data

Industry
Pharmaceutical Preparations
Location
3050 Science Park Road, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Precision IBD, Inc. (to 7/15/2019)

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.33K % +41.1%
Debt-to-equity 13.2 % -4.97%
Return On Equity -33.5 % +23.7%
Return On Assets -29.6 % +23.3%
Operating Margin -4.06K % -137%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 47.8M shares +22.4%
Common Stock, Shares, Outstanding 47.7M shares +22.1%
Entity Public Float 873M USD +18.3%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 47.5M shares +21.7%
Weighted Average Number of Shares Outstanding, Diluted 47.5M shares +21.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 4M USD -36.5%
Research and Development Expense 121M USD +46.9%
General and Administrative Expense 45M USD +43.6%
Operating Income (Loss) -162M USD -50.8%
Nonoperating Income (Expense) 11.8M USD +25993%
Net Income (Loss) Attributable to Parent -151M USD -39%
Earnings Per Share, Basic -3.53 USD/shares -73.9%
Earnings Per Share, Diluted -3.53 USD/shares -4.88%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 113M USD -50.1%
Accounts Receivable, after Allowance for Credit Loss, Current 1.03M USD -4.63%
Assets, Current 726M USD +209%
Property, Plant and Equipment, Net 3.7M USD +50.9%
Operating Lease, Right-of-Use Asset 27.3M USD +87.1%
Assets 758M USD +199%
Accounts Payable, Current 1.16M USD -35.9%
Employee-related Liabilities, Current 2.04M USD +26.2%
Liabilities, Current 19.3M USD +11.6%
Operating Lease, Liability, Noncurrent 26M USD +89.2%
Liabilities 60.8M USD +29.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -232K USD
Retained Earnings (Accumulated Deficit) -372M USD -68%
Stockholders' Equity Attributable to Parent 698M USD +237%
Liabilities and Equity 758M USD +199%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -39.5M USD -34.6%
Net Cash Provided by (Used in) Financing Activities 52.8M USD +42826%
Net Cash Provided by (Used in) Investing Activities -192M USD -20040%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 47.7M shares +22%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -179M USD -493%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 292M USD +13.7%
Deferred Tax Assets, Valuation Allowance 94.5M USD +121%
Deferred Tax Assets, Gross 103M USD +140%
Operating Lease, Liability 29.5M USD +101%
Depreciation 200K USD -44.6%
Payments to Acquire Property, Plant, and Equipment 530K USD -44.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -151M USD -26.9%
Lessee, Operating Lease, Liability, to be Paid 45.6M USD +98.1%
Property, Plant and Equipment, Gross 4.97M USD +68.6%
Operating Lease, Liability, Current 3.49M USD +291%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.18M USD +112%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.06M USD +112%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +12.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 16.1M USD +92.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.31M USD +112%
Deferred Tax Assets, Operating Loss Carryforwards 50M USD +54.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 40M shares 0%
Unrecognized Tax Benefits 4.22M USD +117%
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.44M USD +112%
Operating Lease, Payments 718K USD +897%
Additional Paid in Capital 1.07B USD +150%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 233K USD +168%
Deferred Tax Assets, Net of Valuation Allowance 7.97M USD +11791%
Share-based Payment Arrangement, Expense 27M USD +105%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%